Request a meeting to provide an update on the expansion of CAR-T therapy in Canada and to get ADM Moneo's perspective on how Novartis can work together with the BC Ministry of Health to facilitate local administration of CAR-T treatment for BC citizens who require this therapy. Discuss the best path forward to enable and facilitate BC patients eligible for KYMRIAH® (tisagenlecleucel) to be treated in their home province.
Background: In September of 2018, KYMRIAH® (tisagenlecleucel),) became the first ever chimeric antigen receptor T cell (CAR-T) therapy approved by Health Canada, marking a significant step forward in cancer treatment.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|